This is a corrigendum to: Dimpy Koul, Ruijun Shen, Yong-Wan Kim, Yasuko Kondo, Yiling Lu, Jim Bankson, Sabrina M. Ronen, D. Lynn Kirkpatrick, Garth Powis, W. K. Alfred Yung, Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma, Neuro-Oncology, Volume 12, Issue 6, June 2010, Pages 559–569, https://doi.org/10.1093/neuonc/nop058
In 2024, a reader alerted the Editors to concerns regarding duplication in Figure 1, which concerns have also been raised via PubPeer (https://pubpeer.com/publications/30FC67CBA3437F5843A4AEBBA64D40). The blots for T-Akt and Actin for U251 cells were mistakenly duplicated for the other two cell types shown.
The age of the paper means the authors are no longer able to supply original data or otherwise clarify the error. As part of the inquiry into Figure 1, the authors confirmed that this error does not modify the other results and overall conclusions, and readers are referred to other studies that show similar results.1-12
The authors apologize for this error and any inconvenience this may have caused.
The Editor is satisfied with the authors’ response and agree with the authors’ assertions that the other results and overall conclusions of the article are unaffected by this error.
References
- 1. Peek GW, Tollefsbol TO. Combinatorial PX-866 and Raloxifene Decrease Rb Phosphorylation, Cyclin E2 Transcription, and Proliferation of MCF-7 Breast Cancer Cells. J Cell Biochem. 2016;117:1688-96. https://onlinelibrary.wiley.com/doi/10.1002/jcb.25462 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Peek GW, Tollefsbol TO. Down-regulation of hTERT and Cyclin D1 transcription via PI3K/Akt and TGF-β pathways in MCF-7 Cancer cells with PX-866 and Raloxifene. Exp Cell Res. 2016;344:95-102. https://www.sciencedirect.com/science/article/pii/S0014482716300623?via%3Dihub [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Harder BG, Peng S, Sereduk CP, Sodoma AM, Kitange GJ, Loftus JC, Sarkaria JN, Tran NL. Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells. Mol Med. 2019;25:49. doi: 10.1186/s10020-019-0116-z. https://molmed.biomedcentral.com/articles/10.1186/s10020-019-0116-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Liang T, Gu L, Kang X, Li J, Song Y, Wang Y, Ma W. Programmed cell death disrupts inflammatory tumor microenvironment (TME) and promotes glioblastoma evolution. Cell Commun Signal. 2024;22:333. https://biosignaling.biomedcentral.com/articles/10.1186/s12964-024-01602-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, Sukumar S, Nelson SJ, Vigneron DB, Kurhanewicz J, James CD, Haas-Kogan DA, Ronen SM. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res. 2010;70:1296-305. https://aacrjournals.org/cancerres/article/70/4/1296/561189/Noninvasive-Detection-of-Target-Modulation [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Gwak HS, Kim TH, Jo GH, Kim YJ, Kwak HJ, Kim JH, Yin J, Yoo H, Lee SH, Park JB. Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines. PLoS One. 2012;7: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0047449 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Pearson JRD, Regad T. Targeting cellular pathways in glioblastoma multiforme. Signal Transduct Target Ther. 2017;2:17040. https://www.nature.com/articles/sigtrans201740 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Tanaka S, Batchelor TT, Iafrate AJ, Dias-Santagata D, Borger DR, Ellisen LW, Yang D, Louis DN, Cahill DP, Chi AS. PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. Acta Neuropathol Commun. 2019;7:66. https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-019-0720-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST, Li WP. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer. 2017;16:100. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-017-0670-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Gwak HS, Shingu T, Chumbalkar V, Hwang YH, DeJournett R, Latha K, Koul D, Alfred Yung WK, Powis G, Farrell NP, Bögler O. Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. Int J Cancer. 2011;128:787-96. doi: 10.1002/ijc.25394 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Kim YW, Liu TJ, Koul D, Tiao N, Feroze AH, Wang J, Powis G, Yung WK. Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. Neuro Oncol. 2011;13:367-75. doi: 10.1093/neuonc/nor012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald D, Eisenstat DD, Kakumanu AS, Salim M, Chalchal H, Squire J, Tsao MS, Kamel-Reid S, Banerji S, Tu D, Powers J, Hausman DF, Mason WP. Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol. 2015;17:1270-4. doi: 10.1093/neuonc/nou365 [DOI] [PMC free article] [PubMed] [Google Scholar]